No Record Found
Sector
PharmaceuticalsOpen
₹33Prev. Close
₹33.26Turnover(Lac.)
₹13.52Day's High
₹33.95Day's Low
₹32.8952 Week's High
₹56.952 Week's Low
₹31.2Book Value
₹42.03Face Value
₹10Mkt Cap (₹ Cr.)
70.31P/E
8.02EPS
4.11Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | 
|---|---|---|---|---|
| Equity Capital | 24.43 | 14.9 | 14.9 | 14.95 | 
| Preference Capital | 0 | 0 | 0 | 0 | 
| Reserves | 53.75 | 39.49 | 36.97 | 32.19 | 
| Net Worth | 78.18 | 54.39 | 51.87 | 47.14 | 
| Minority Interest | 
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 | 
|---|---|---|---|---|
| Revenue | 55.35 | 47 | 34.12 | 28.58 | 
| yoy growth (%) | 17.76 | 37.72 | 19.39 | 60.68 | 
| Raw materials | -8.55 | -9.56 | -8.14 | -8.79 | 
| As % of sales | 15.45 | 20.35 | 23.86 | 30.78 | 
| Employee costs | -9.99 | -7.58 | -5.49 | -4.34 | 
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 | 
|---|---|---|---|---|
| Profit before tax | 4.25 | 4 | 2.83 | 0.78 | 
| Depreciation | -5.17 | -4.63 | -3.9 | -3.35 | 
| Tax paid | 0.18 | -0.88 | -0.33 | 0.12 | 
| Working capital | 8.28 | 4.54 | 4.71 | 8.12 | 
| Other operating items | 
| Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 | 
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | 17.76 | 37.72 | 19.39 | 60.68 | 
| Op profit growth | 14.62 | 42.61 | 105.79 | 32.15 | 
| EBIT growth | 15.34 | 54.58 | 230.95 | 76.34 | 
| Net profit growth | 42.28 | 24.72 | 175.16 | 96.62 | 
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | 
|---|---|---|---|---|---|
| Gross Sales | 46.67 | 45.45 | 52.23 | 51.39 | 51.78 | 
| Excise Duty | 0 | 0 | 0 | 0 | 0 | 
| Net Sales | 46.67 | 45.45 | 52.23 | 51.39 | 51.78 | 
| Other Operating Income | 0 | 0 | 0 | 0 | 0 | 
| Other Income | 4.8 | 0.04 | 0.04 | 0.1 | 0.08 | 
| Company Name | LTP (₹) | P/E  (%) | Mkt.Cap  (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield  (%) | Sales Qtr  (₹.Cr) | Book Value (₹) | 
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,703.6 | 82.06 | 4,08,750.71 | 753.53 | 0.94 | 5,566.68 | 101.44 | 
| Divis Laboratories Ltd DIVISLAB | 6,653.65 | 75.61 | 1,76,633.5 | 557 | 0.45 | 2,357 | 561.08 | 
| Cipla Ltd CIPLA | 1,540.5 | 23.94 | 1,24,437.16 | 1,210.53 | 1.04 | 4,495.16 | 411.56 | 
| Torrent Pharmaceuticals Ltd TORNTPHARM | 3,600.9 | 61.3 | 1,21,865.35 | 551 | 0.17 | 2,567 | 224.34 | 
| Mankind Pharma Ltd MANKIND | 2,445.75 | 55.79 | 1,00,950.41 | 412.76 | 0 | 2,541.36 | 354.69 | 
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Kalyan Ram Mangipudi
Whole-time Director
Alangudi Sankaranarayanan
Independent Director
Kunda Kalpana
Non Executive Director
Karopadi Shivanand Nayak
Whole Time Director & Chief Financial Officer
K Sri Kalyan
Independent Director
Shyam Sunder Tipparaju
Company Sec. & Compli. Officer
A V Kiran
Additional Director
Satyanarayan Vedula
Additional Director
Priya Rajender Goda
Survey #349/A Pregnapur Vlge,
Telangana - 502311
Tel: -
Website: http://www.vivobio.com
Email: investors@vivobio.com
1-2-285,
Domalguda, J B Apartments,
Hyderabad - 500 029
Tel: 91-40-27642217 /2763
Website: www.aarthiconsultants.com
Email: info@aarthiconsultants.com
Summary
Vivo Bio Tech Limited, established in February, 1987 is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAAL...
Read More
Reports by Vivo Bio Tech Ltd








 IIFL Customer Care Number
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
 IIFL Capital Services Support WhatsApp Number
+91 9892691696


IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.